Skip to main content
MTHRY logo

M3, Inc. (MTHRY) Stock Price & Analysis

M3, Inc. (MTHRY) — price $5.35 (0.00%), as of the Nov 19, 2026 trading session; market cap $7.11B.

Educational signal · not a buy or sell recommendation · How to read this

$5.35 $0.00 (0.00%) Market Cap $7.11B

M3, Inc. · MTHRY · Healthcare · Medical - Healthcare Information Services

M3, Inc., established in Tokyo, Japan, in 2000, and formerly known as So-netM3, Inc. until its rebranding in January 2010, specializes in delivering a broad range of internet-based services, primarily targeting physicians…

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • TXG · 10x Genomics, Inc. · 38 /100
  • HQY · HealthEquity, Inc. · 90 /100
  • HNGE · Hinge Health, Inc. · 97 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$5.35
Change on the day0.00%
52-week range$3.97–$8.84
Market capitalisation$7.11B—
Price / earnings (trailing)25.29
Shares traded on the day366
Beta (volatility vs the S&P 500)0.48
Dividends per share (last 12 months)$0.04
Dividend yield (last 12 months)0.74%

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $4.23, high $8.83, latest $5.35. 2 reported quarters marked. $8.83 $4.23 high $8.83 Feb 9, 2026 · Earnings results · no recorded estimate to compare · close $5.591Apr 30, 2026 · Earnings results · no recorded estimate to compare · close $4.752 Oct 17, 2025 Nov 19, 2026 · $5.35 $7.16Oct 17, 2025$6.99Oct 31, 2025$8.83Nov 14, 2025$8.19Nov 28, 2025$6.50Dec 12, 2025$6.63Dec 26, 2025$6.97Jan 9, 2026$6.34Jan 23, 2026$5.59Feb 6, 2026$5.15Feb 20, 2026$5.11Mar 6, 2026$4.86Mar 20, 2026$5.16Apr 2, 2026$5.01Apr 17, 2026$4.75May 1, 2026$4.23May 15, 2026$4.44May 29, 2026$4.99Jun 12, 2026$5.49Jun 26, 2026$5.74Jul 10, 2026$5.50Jul 24, 2026$4.82Aug 7, 2026$5.30Aug 21, 2026$5.65Sep 4, 2026$5.58Sep 18, 2026$5.50Oct 2, 2026$5.99Oct 16, 2026$5.77Oct 30, 2026$5.69Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results
  • · Earnings results

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Other perspectives

Council score for M3 (MTHRY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Oct 1, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Strong
Debt/Equity Strong
ROE Neutral
Gross Margin Moderate

Read on: Oct 1, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Oct 1, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is M3 (MTHRY), and what does it report?

Short answer

M3, Inc., established in Tokyo, Japan, in 2000, and formerly known as So-netM3, Inc. until its rebranding in January 2010, specializes in delivering a broad range of internet-based services, primarily targeting physicians… Healthcare / Medical Healthcare Information Services Headquarters: Akasaka Intercity, Tokyo, TY, 107-0052, JP. It employs 17,010 people and is led by Itaru Tanimura. In Q2 FY2027 it reported revenue of ¥91.68B and net income of ¥10.92B. The market values it at $7.11B.

2 · Latest results

What do the latest results show for M3 (MTHRY)?

Short answer · as of

The most recent reported quarter, Q2 FY2027, carried revenue of ¥91.68B.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$554.30M Apr 30, 2026
Latest report · revenue estimate
$565.36M Apr 30, 2026
Latest report · revenue vs estimate
Below estimate Apr 30, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Apr 30, 2026$554.30M$565.36M$0.0354Not available
Feb 9, 2026$607.46M$609.56M$0.0908Not available
Oct 28, 2025$574.25M$559.83M$0.0544Not available
Jul 28, 2025$595.24M$570.08M$0.0004Not available
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2027¥91.68B¥10.92B¥8.18 (diluted)
Q1 FY2027¥91.29B¥9.19B¥6.88 (diluted)
Q4 FY2026¥88.57B¥7.59B¥5.66 (diluted)
Q3 FY2026¥95.20B¥19.28B¥14.21 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for M3 (MTHRY)?

Short answer · as of

The distress and quality screens read Altman Z 5.30 · Piotroski F 5. Trailing ratios: ROE 11.3% · ROA 7.0% · current ratio 2.44 · earnings yield 3.8%.

4 · What to check next?

What should you watch next at M3 (MTHRY)?

Research dated 2026-09-13.

Investors monitoring the stock should track whether actual revenue can close the gap with analyst projections, as recent periods have shown actual results trailing consensus estimates.

Another key observation point is the progression of the international segment, particularly the European and American practitioner networks. Continued scaling in those overseas portals is required to validate the strategy of replicating its domestic pharmaceutical marketing success in foreign regulatory environments.

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

5 · Score methodology

How is M3 scored?

Unlike conventional digital advertising networks that monetize broad consumer traffic, this platform generates value exclusively through a highly restricted audience of medical practitioners.

When compared to traditional contract research organizations or healthcare staffing firms, this business derives its advantage from a captive user base, allowing it to source clinical trial participants and job candidates directly from its own portals. This integrated approach reduces acquisition costs significantly compared to standalone medical recruiters.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Named competitor$58.79 Nov 19, 2026$12.2B— Model unavailable
Bangkok Dusit Medical Services Public Company Limited (BDUUF) Named competitor$0.64 Nov 19, 2026$10.2B— Model unavailable
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) Named competitor$1.46 Nov 13, 2026$8.46B— Model unavailable
Demant A/S (WILLF) Named competitor$53.40 Nov 19, 2026$11.3B— Model unavailable
Grifols, S.A. (GIFLF) Named competitor$12.72 Nov 19, 2026$8.66B— Model unavailable
10x Genomics, Inc. (TXG) Same industry, near in market value$57.07 Nov 18, 2026$7.51B— 5-pillar · not comparable
HealthEquity, Inc. (HQY) Same industry, near in market value$97.31 Nov 18, 2026$8.05B— 5-pillar · not comparable
Hinge Health, Inc. (HNGE) Same industry, near in market value$114.53 Nov 18, 2026$9.31B— 5-pillar · not comparable
Doximity, Inc. (DOCS) Same industry, near in market value$29.61 Nov 19, 2026$5.28B— 5-pillar · not comparable
Tempus AI, Inc. (TEM) Same industry, near in market value$63.62 Nov 18, 2026$11.6B— 5-pillar · not comparable
HeartFlow, Inc. (HTFL) Same industry, near in market value$45.89 Nov 18, 2026$4.03B— 5-pillar · not comparable
BrightSpring Health Services, Inc. (BTSG) Same industry, near in market value$64.02 Nov 19, 2026$12.7B— 5-pillar · not comparable

The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held MTHRY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported MTHRY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About MTHRY (Healthcare)

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

Is MTHRY a good stock to buy?

Stock Expert AI does not rate MTHRY buy, sell or hold. M3, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the MTHRY stock price today?

The last price recorded for M3, Inc. (MTHRY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for MTHRY?

Evaluate MTHRY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.

How frequently does MTHRY data refresh on this page?

MTHRY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven MTHRY's recent stock price performance?

(MTHRY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive global network of healthcare professionals on its digital platforms. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MTHRY overvalued or undervalued right now?

(MTHRY) trades at 25.29x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research MTHRY before investing?

Before investing in M3, Inc. (MTHRY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding MTHRY to a portfolio?

Key strength of M3, Inc. (MTHRY): Extensive global network of healthcare professionals on its digital platforms. Weigh rewards against risks and diversify. Not financial advice.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 34 figures on this page — 27 from Financial Modeling Prep (FMP), 3 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • 4. What should you watch next at M3 (MTHRY)?: Reported versus estimated, last 8 quarters; Analyst revenue and earnings estimates (average); Business description
  • 5. How is M3 scored?: Business description; Trailing twelve-month ratio set; Sector / industry (provider taxonomy)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.